Genelux Q3 EPS Lowered by Brookline Capital Management

Genelux Corporation (NASDAQ:GNLX) – Research analysts at Brookline Capital Management decreased their Q3 2025 EPS estimates for shares of Genelux in a research note issued on Tuesday, August 12th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.21) per share for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s FY2025 earnings at ($0.82) EPS.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02.

Other analysts have also recently issued research reports about the stock. Benchmark decreased their price target on shares of Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Genelux from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. Finally, HC Wainwright reiterated a “buy” rating on shares of Genelux in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Genelux currently has an average rating of “Buy” and a consensus target price of $17.75.

Genelux Stock Up 4.4%

Shares of GNLX stock opened at $3.56 on Friday. The stock has a market cap of $134.46 million, a P/E ratio of -4.14 and a beta of -0.32. Genelux has a 52 week low of $1.95 and a 52 week high of $5.89. The company’s fifty day simple moving average is $3.18 and its two-hundred day simple moving average is $3.24.

Institutional Trading of Genelux

Large investors have recently made changes to their positions in the business. Private Management Group Inc. bought a new stake in shares of Genelux in the 2nd quarter worth about $33,000. Advisor Resource Council bought a new position in Genelux during the 1st quarter valued at about $34,000. Raymond James Financial Inc. bought a new position in Genelux during the 4th quarter valued at about $41,000. Liberty Wealth Management LLC bought a new position in Genelux during the 1st quarter valued at about $45,000. Finally, 5T Wealth LLC bought a new position in Genelux during the 1st quarter valued at about $49,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.